Int J Oncol. 1996 Jul;9(1):179-82. doi: 10.3892/ijo.9.1.179.
Among the many immunological events associated with successful intravesical bacillus Calmette Guerin (BCG) immunotherapy of bladder cancer is the induction of a wide range of cytokines including the T helper 2 (T(H)2) designated cytokines Interleukin-6 (IL-6) and IL-10, but not IL-4, in the urine of the patients. The aim of this work was to determine if this treatment resulted in the production of IL-5, a classical T(H)2 cytokine. Following treatment using ELISA this cytokine was detected in the urine of all patients examined confirming that intravesical BCG therapy does not induce in bladder cancer patients solely a T(H)1 response but rather T(H)1/2 or T(H)0 like response.
在与膀胱癌经膀胱内卡介苗(BCG)免疫治疗成功相关的众多免疫学事件中,包括白细胞介素-6 (IL-6)和 IL-10 等多种细胞因子的诱导,这些细胞因子被指定为 T 辅助 2 (T(H)2)细胞因子,但 IL-4 除外,在患者的尿液中。本工作的目的是确定这种治疗是否导致产生 IL-5,一种经典的 T(H)2 细胞因子。通过 ELISA 检测,在所有接受检查的患者的尿液中均检测到这种细胞因子,证实经膀胱内 BCG 治疗不仅会诱导膀胱癌患者产生 T(H)1 反应,还会诱导 T(H)1/2 或 T(H)0 样反应。